T he distinction between Crohn's disease (CD) and ulcerative colitis (UC) is supported by clinical, radiological, endoscopic, and pathological information. 1 Unfortunately, in 10%-15% of patients the distinction cannot be made easily, so that the term indeterminate colitis (IC) has been adopted in such cases. 2 However, the term has been used with different definitions, leading to considerable confusion. 3 Following the report of the Montreal Working Party in 2005, it was proposed that the term indeterminate colitis should be reserved for cases in which a surgical specimen is available, while the term inflammatory bowel disease type unclassified (IBDU) should be used for patients who present divergent clinical, endoscopic, and histological features and for whom no surgical specimen is available. 2, 4 The definition of IBDU is not merely for academic purposes, as epidemiological data have shown that the clinical course and prognosis of IBDU can be worse than UC, particularly because of the higher rate of pouch failure and long-term complications. 2 The measurement of serological markers such as anti-Saccharomyces cerevisiae (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (pANCA) has been proposed as a method to differentiate CD from UC. Joossens et al 5 performed a prospective study to determine whether ASCA or pANCA may be useful in classifying patients with IBDU. Results of this study have demonstrated that serological markers may be helpful in predicting the course of patients with IBDU. However, patients with an initial diagnosis of IBDU and negative serology were more likely to remain indeterminate and it was proposed that these patients may reflect a distinct clinicoserological subgroup of inflammatory bowel disease (IBD).
Capsule endoscopy (CE) has revolutionized the study of the small bowel by providing a reliable method to endoscopically evaluate the entire small bowel. The available data suggest that CE can identify small-bowel mucosal lesions not observed through other imaging techniques and it may therefore play an important diagnostic role in the evaluation of some patients with known or suspected CD. 6 Several studies have examined the potential role of CE in the setting of IBDU/IC, suggesting that CE is useful in the work-up of these patients by ruling out small-bowel lesions suggestive of CD. [6] [7] [8] Despite these new developments, a long-term follow-up is often the only way to determine the correct diagnosis. The aim of our study is to evaluate the clinical impact of CE on long-standing IBDU and IC patients with negative serology. We focused on these patients because there is less information available on this subgroup of IBD, for which there is thus a greater need to find an alternative method of diagnosis.
MATERIALS AND METHODS

Patients
Eighteen consecutive patients with long-standing IBDU/IC and negative serology were selected. They were included in our study from 2004, undergoing a CE examination, and then followed until the present time (mean follow-up of 31.6 6 10.6 months).
The IBDU group consisted of 14 patients (7 females, mean age 40 6 12 years), with a duration of disease of 5.8 6 3.3 years (2.5-16 years), whose clinical course did not show correspondence between clinical, endoscopic, and histological features. The IC group consisted of 4 patients (2 females, mean age 41 6 6 years) with a duration of disease of 8.9 6 5.5 years (2-10.5 years) for whom a surgical specimen was available.
Data were collected by reviewing the clinical records including age, sex, clinical presentation, endoscopic and pathological features, serological results, and past and current medication. The patients' characteristics are shown in Tables 1 and 2 . Seven patients had previously been treated with azathioprine/6-mercaptopurine, cyclosporine, or infliximab (Tables 1, 2) .
They showed no evidence of obstructive symptoms and were not taking nonsteroidal antiinflammatory drugs (NSAIDs), aspirin, clopidogrel, or warfarin in the month prior to the examination. None of the CE examinations was conducted during hospitalization or disease exacerbation. A previous examination of the small bowel (standard ileoscopy or radiology) was negative in all cases.
CE Procedure
A PillCam SB (Given Imaging, Yoqneam, Israel) was used. The patients fasted for 12 hours before the examination. Approximately 10 minutes before ingestion of the capsule 10 mg of metoclopramide was taken orally. The capsule was swallowed with a glass of water containing simethicone. All patients were advised to start drinking water after 2 hours and to have a liquid meal 4 hours after capsule ingestion. After 8 hours the sensor array and the recording device were removed. The digital video image streams of the examinations were downloaded into the RAPID system. The images were then visualized by 2 observers, using the CE structured terminology 9 and were described according to the following classification.
Outcome Measures
Lesions considered diagnostic of CD by CE were 4 or more erosions/ulcers ( Fig. 1) and/or the presence of a stricture, and these patients were classified as Group 3. Patients presenting subtle findings such as focal villi denudation ( Fig. 2 ), isolated erosion ( Fig. 3) , or fewer than 4 erosions/ulcers were considered to belong to Group 2. A normal examination (Fig. 4 ) was described as Group 1.
We assumed a definitive diagnosis when the disease evolved to the point that a diagnosis of CD or UC was rendered by new data obtained from clinical, laboratory, radiological, endoscopic (including the CE findings), and pathological information.
CD was definitively diagnosed when there was characteristic small-bowel involvement, when fistula occurred, or when granulomas were found at biopsy.
1 Small-bowel involvement was recognized by the presence of lesions separated by normal mucosa, transmural involvement with fissuring ulcers, and fistula and development of strictures. Small-bowel lesions were defined as so-called ''typical ulcerations'' corresponding to excavated lesions (erosions and ulcers) described in the CE structured terminology. 9 Mow et al 13 described ulcers as white lesions within a crater and with surrounding erythema, whereas superficial white lesions with surrounding erythema were characterized as erosions. The definitive diagnosis of UC was based on a surgical specimen with diffuse involvement starting distally and with an absence of transmural inflammation. For cases in which only endoscopic samples were available the diagnosis was based on diffuse colonic inflammation, distally more intense, and normal small-bowel mucosa. 1 
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RESULTS
The capsule reached the cecum in all patients. Median gastric transit time and small-bowel transit time were 31.6 6 17 minutes (3-90) and 3.5 6 1.6 hours (1.51-7.47), respectively. The procedure was well tolerated and there were no cases of capsule retention or any other adverse event.
The examination was normal in 2 patients (Group 1). Pathological findings detected in the other 16 patients were limited to the mid-small bowel (jejunum and proximal ileum) in 8 cases, to the distal small-bowel or terminal ileum in 1, and throughout the entire small bowel in 7 cases. In 9 patients subtle findings were observed (Group 2): focal villi denudation in 1 patient, isolated erosion in another patient, and fewer than 4 erosions/ulcers, with a median of 2 lesions, in the remaining 7 patients (Table 3 ). In 7 patients CE detected significant lesions (Group 3) leading to a CD diagnosis: 4 ulcers in 1 patient, 6 or more erosions (a median of 8) in 3 patients, and finally, both ulcers and erosions (a median of 7 and 38, respectively) in the remaining 3 patients (Table 3) . Besides the capsule findings, the clinical strategy was maintained in these last 7 patients: 4 of them are taking mesalamine, 1 is being treated with budesonide, 1 is being kept on 6-mercaptopurine, and the last is asymptomatic without medication. Despite a nonspecific or a negative CE, a definitive diagnosis was achieved in 2 additional patients after a mean duration of disease of 6 years. CD was diagnosed in 1 case from Group 2, 1 month after CE, in relation to the emergence of a rectovaginal fistula in distal colitis with rectal sparing. This patient was reassessed and started on infliximab infusions. In another case, UC was diagnosed following proctocolectomy performed 1 year after a negative CE in a Group 1 patient who had previously been submitted to a subtotal colectomy to treat a toxic megacolon.
Nine patients remain with a diagnosis of IBDU/IC with a mean disease duration of 9.6 6 4 years (5-17). Of these 9, 8 patients are from Group 2 and 1 from Group 1: 3 are taking mesalamine, 2 maintain infliximab infusions, 2 are being kept on azathioprine and methotrexate, respectively, and the last 2 patients are asymptomatic without medication.
DISCUSSION
CE can detect mucosal inflammatory changes of the small intestine often missed by other imaging techniques. In a pooled data analysis, CE had a miss rate for ulcers of only 1%. 10 Moreover, a meta-analysis comparing CE to other imaging methods to observe the small bowel for IBD has established that CE has an incremental diagnostic yield of 25%-40% superior to that of other techniques. 11 On the other hand, published reports on the yield of CE are conditioned by the lack of a validated CE scoring index that would allow the presence of CD to be predicted. 12 Mow et al 13 used the empirical cutoff of 3 ulcers of any size at CE to establish a diagnosis of CD, but Fidder et al 14 defined a positive capsule study for CD by the presence of 4 or more ulcers, erosions, or a region with clear exudate and mucosal hyperemia and edema. Buchman et al 15 graded CE videos as grade 0 (normal), grade 1 (erythema, isolated villi loss), grade 2 (erosion, no ulcer), or grade 3 (ulcers, spontaneous bleeding and/or stricture). Gal et al 16 divided the small bowel into 2 on the basis of small-bowel transit time and rated each segment for 3 components: an inflammation score, an extent of disease score, and a narrowing score. More recently, Gralnek et al 17 created a scoring index based on 3 capsule endoscopic variables: villous appearance, ulcers, and stenosis. The number of lesions was defined as single, few (2-7 lesions), or multiple (8 or more lesions). A score below 135 is classified as normal or clinically insignificant mucosal inflammatory change and a score higher than 790 is classified as moderate to severe.
It must be remembered, however, that there are pathological conditions in which small-bowel permeability is increased and that all these conditions may have small intestinal erosions and ulcers. They include NSAID intake, lymphoid hyperplasia, lymphoma, radiation enteritis, human immunodeficiency virus with opportunistic infection, intestinal tuberculosis, and Behçet's disease. 18 Therefore, it is important to exclude all these pathological conditions before a final diagnosis of CD is made. Until now, none of the above-mentioned conditions has been diagnosed in our patients. On the other hand, Goldstein et al 19 reported that 11% of healthy volunteers had small-intestine mucosal breaks, even in the absence of NSAID intake. Graham et al 20 showed that the most severe damage among the nonusers of NSAID controls was 1 small erosion, none of them having 4 or more erosions. These results led us to consider 4 or more erosions/ulcers, or the presence of a stricture, as lesions diagnostic of small-bowel CD. A limitation of our study is the absence of a control group of asymptomatic UC patients to be used as a reference in order to ascertain the baseline frequency of small-bowel lesions in such patients. However, in clinical practice routine evaluation of the small bowel by CE in asymptomatic patients is not indicated and, therefore, CE may be most clinically useful in a setting in which UC is refractory to medical treatment, or when presenting atypical clinical features, as well as in the case of previous colectomy. 21 Approximately 10% of patients with an initial diagnosis of UC will be reclassified as having either CD or IBDU at follow-up. 21 In 1 retrospective study, 19 patients out of 120 (16%), with an established diagnosis of UC and atypical symptoms (10%), or with medically refractory disease (9%), or with prior colectomy for UC and new intestinal complaints (33%), or those with IBDU (17%), could be reclassified as having CD based on the presence of typical small-bowel ulcerations (defined as the presence of 3 or more ulcerations) seen at CE. 8 In the setting of IBDU/IC, several studies on the benefit of CE for its evaluation have been published. [6] [7] [8] These small pilot studies found that the use of CE led to a change in the diagnosis of 29%-40% of patients. 6 A recent multicenter study 7 looked at 30 seronegative IBDU/IC patients with a mean duration of disease of 6 years (range 1-18). An initial CE was positive in 5 patients, with a mean duration of disease of 4 years (range 1-9), who were later diagnosed with CD. The remaining 25 patients, who had negative capsules, were then followed clinically for 7 years, during which time CE was not repeated. Five more patients were eventually diagnosed as having CD and 2 as having UC, whereas the diagnosis of the other 18 patients remained indeterminate. Patients with CD gained a reassessment of their treatment. In the present study, CE enabled the detection of small-bowel lesions diagnostic of CD in 7 patients out of 18 with IC/IBDU (39%), leading to a definitive diagnosis. We feel confident in the diagnosis of CD in these patients since, in all cases, CE displayed excavated lesions described in the CE terminology that are usually considered strongly suggestive of CD. 9 However, retrospectively, in none of them was the clinical strategy changed by the knowledge of these findings, in contrast with the previous study. This group showed a clinical heterogeneity ranging from asymptomatic with no medication to chronic, continuous illness that requires immunosuppressive drugs for its control.
Although a negative CE has a very high negative predictive value, we cannot exclude a diagnosis of CD. In fact, CE presents false negatives 22 caused by the miss rate (11%), incomplete examination (in up to 25%), technical limitations (battery life duration, field of view), and suboptimal cleanness of the small bowel (in up to 33%).
It must also be remembered that capsule examination was not repeated in the present study and these patients (most of them under treatment) may have macroscopic mucosal abnormalities in the small intestine that can heal completely and relapse later. Thus, despite a nonspecific CE, 1 patient in the present series has evolved to a definitive diagnosis of CD during follow-up management, leading to a change in therapy.
It has often been emphasized that IBDU may be a temporary diagnosis. Joossens et al 5 showed that a definitive diagnosis of CD or UC within 6 years following disease onset was reached in 32% of patients. However, 40 (85%) of their 47 patients with IBDU and negative serology remained indeterminate at follow-up. In our study, 50% of patients still have IBDU/IC, further emphasizing the hypothesis that these patients with long-standing ''indeterminate'' disease and negative serology may belong to an original subgroup of IBD.
These results confirm the ambiguity in relation to the real value of CE in this heterogeneous IBD group. Thus, larger prospective studies are needed to confirm its usefulness in this setting, as well as to standardize criteria for CD at CE.
We conclude that, although in patients with longstanding IBDU/IC and negative serology, CE can detect small-bowel lesions which lead to a CD diagnosis in a significant proportion of patients (39% in our series), this finding did not bring about a modification of the clinical management. Moreover, the single case in which a CD diagnosis ultimately developed, leading to a change in therapy, presented only subtle findings at CE examination. Our results thus suggest that the capsule's findings are not helpful in the clinical management of these patients.
